Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
Also Read: Glass Lewis Proxy...
BioVaxys Technology Corp., announced that it has entered into an agreement with the Deaconess Research Institute ("DRI") to supply BioVaxys with surgically debulked tumors...
AIkido Pharma Inc. reported that, on April 20, 2022, the independent Proxy Paper analysis firm Glass Lewis issued a report ("GL Report") providing an...
Newlight Technologies announced a nationwide school art competition, encouraging students in grades K-8 to draw an idea that could help save the planet.
Starting today,...
